M E D I C I N E
The aim of the present study is to demonstrate the significance of retinopathy and microalbuminuria, as well as the significance of blockade of the activity of angiotensin II, and thus to blaze the trail for multifactorial therapy of microvascular diabetic modifications.
Methods
Medline was selectively searched for articles published from 1948 to 2008 containing the terms "angiotensin," "microalbuminuria," and "retinopathy" (English and German). The combination of "angiotensin + microalbuminuria" resulted in 786 hits. The combination of "angiotensin + retinopathy" resulted in 452 hits. The results were further amplified by screening the reference sections of the retrieved articles and selected according to relevance for the present review. Among them was a potentially relevant Cochrane review (e8) .
Microalbuminuria

Definition
Increased excretion of albumin in urine is called microalbuminuria (Table) . Thus, microalbuminuria marks the beginning of a progressive development which may lead to terminal renal failure and/or cardiovascular complications in the course of several years. If albumin is excreted below the threshold for microalbuminuria, the term "low-grade albuminuria" is used. This is also accompanied by an increased cardiovascular risk (5) . According to the data of the Framingham study, an increased risk was detectable with >3.9 mg/g creatinine for men and >7.5 mg/g creatinine for women.
Epidemiology
The frequency of microalbuminuria in the population was 8.3% (6) in the NHANES III cohort (USA, 1988-94) . In the PREVEND study, which was conducted in the Netherlands, it was 7.2% (7) . In practices, the prevalence is clearly higher, due to several concomitant cardiovascular diseases:
b The prevalence is about 20% (8) in general medical care in Germany b In practices specializing in diabetes at 39% (e9) b In cardiological practices up to 58% (9) . In the context of these numbers, not enough tests for the appearance of microalbuminuria are performed in daily medical practice (8) .
Microalbuminuria and renal risk
Patients with microalbuminuria have a 10-to 20-fold greater risk of developing manifest diabetic nephropathy (e10) in comparison to patients who do not excrete albumin. From then on, renal function decreases, with an observed annual loss of 3 to 5 mL/min under angiotensin blockade (instead of 12 mL/min without therapy). Meanwhile 30% to 40% of all dialysis patients in Germany suffer from renal insufficiency as a consequence of diabetes. The 5-year survival rate of diabetes patients with renal replacement therapy is 25% (e11).
Possible interventions
Several clinical studies have demonstrated the significance of blockade of the RAS for avoiding the progression of Risk reduction of microvascular changes in the Steno 2 study (3) after 3.8 years on the basis of a standard therapy orientated on the guidelines in comparison to intensified therapy, in patients with type 2 diabetes and microalbuminuria and blood pressure <140/85 mm Hg, near normal blood sugar with an HbA1c <6.5 %, HDL cholesterol >1.1 mmol/L, triglycerides <1.7 mmol/L, and total cholesterol <5.0 mmol/L. OR, Odds Ratio; CI, confidence interval There are already studies on patients with current diabetic nephropathy (10, 11) and on reducing the progression of microalbuminuria (12) for type 2 diabetes. These studies showed that blockade of the AT 1 receptor is superior to standard therapy (without other RAS blocking substances) and to an amlodipine based regimen (absolute risk reduction over 2.6 years: 7.4% irbesartan versus standard therapy, 9.5 % versus amlodipine based therapy [10] ). The annual decrease in the glomerular filtration rate was less over longer treatment periods:
b IDNT (10), period: 2.6 years, decrease: 5.5 mL/min/1.73 m 2 /year b RENAAL (11) (13), 5 years, decrease: 3.7 mL/min/1.73 m 2 /year. These effects are not only the result of blood pressure management, as the example of the analysis in the IDNT study showed (e13). In every quartile of the systolic blood pressure, the effects of RAS blockade were greater than those with placebo or those with calcium antagonists.
In the context of diabetic nephropathy, combinations of RAS blockers for reducing protein are effective and can still be employed according to the results of the ONTARGET study (13, e14) . As an alternative, higher dosages of an AT 1 blocker can be used. Dosages up to 128 mg candesartan were successfully tested in the studies of Schmieder et al. (14) and Burgess et al. (e16) .
Retinopathy
Definition Diabetic retinopathy is evoked by microangiopathy. It causes decreased visual acuity, a restricted visual field and can subsequently lead to blindness. The clinical differentiation is made between non-proliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR) and diabetic macular edema (e18).
NPDR is marked by vascular modifications, such as micro-aneurysms, blot hemorrhages, and cotton wool spots. Progression of the disease leads to perfusion of retinal capillaries: The tissue of the retina becomes ischemic. This leads to venous capillary and to intraretinal microvascular modifications, to further bleeding, and to exsudation. Proliferative diabetic retinopathy (PDR) is characterized by neovascularization. Formation of new blood vessels is often accompanied by areas of bleeding in the vitreous body and sometimes by detachment of the retina. If neovascularization extends into the area of the anterior segment of the eye, newly formed vessels of the iris can close the chamber angle. This results in the development of glaucoma. Diabetic macular edema (DMO) is marked by the breakdown of the blood-retina barrier with increased vascular permeability and is accompanied by retinal edema and hard exudates.
Modifications of the retina are measured by the socalled ETDRS (Early Treatment of Diabetic Retinopathy Study) scale (e17, 16) , which is based on the Airlie House Classification of Diabetic Retinopathy (15) (Figure 3 ).
Epidemiology
Diabetes is the most common cause of blindness in patients of working age. In the USA, about 3.6% of patients with type 1 diabetes and 1.6% of patients with type 2 diabetes are affected by this. In England and Wales, about 1000 patients become blind each year from diabetes (e19). The prevalence of diabetic retinopathy is between 0% and 3% in type 1 diabetics at the time of the diagnosis of diabetes. The prevalence in type 2 diabetes is between 6.7 and 30.2%. The prevalence and the severity of diabetic retinopathy particularly increase with the duration of diabetes (e20).
Retinopathy and blindness
Most of the patients with type 1 diabetes and more than 60% of the patients with type 2 diabetes who have had the disease for 20 years develop diabetic retinopathy (e21). This is linked to a clear reduction in
Cumulative incidence of cardiovascular events and death from cardiovascular causes such as non-fatal stroke, non-fatal myocardial infarction, coronary bypass surgery, percutaneous coronary intervention, revascularization and amputation, in the Steno 2 study (4) . Comparison between conventional standard therapy orientated on the guidelines and intensified therapy in patients with type 2 diabetes and microalbuminuria and blood pressure <140/85 mm Hg, near normal blood sugar with HbA1c <6.5%, HDL cholesterol >1.1 mmol/L, triglycerides <1.7 mmol/L, and total cholesterol <5.0 mmol/L.
FIGURE 2
the quality of life. In a study of Brown et al., patients stated that they would be willing to swap (e22) 40% of their remaining life span for elimination of ocular disease.
Possible interventions
There are many clinical studies in which the significance of blockade of the renin-angiotensin system (RAS) (Figure 4) for the prevention and treatment of diabetic retinopathy was examined. This includes three smaller studies (e23-e25) , as well as the EUCLID study (16) . EUCLID compared the ACE inhibitor lisinopril with placebo in 530 patients with type 1 diabetes (16) . The probability ratio for the progression of retinopathy was 0.5 under lisinopril in comparison to placebo. However, at the start of the study, the HbA1c values in the lisinopril group were 0.4% less than in the control group and this led to a slightly greater decrease in blood pressure under the ACE inhibitor (3 mm Hg).
A multicenter study over a period of 5 years with 11 140 patients with type 2 diabetes (ADVANCE) examined the significance of a decrease in blood pressure and strict control of blood sugar on macrovascular events (17) . One of the secondary target parameters was the reoccurrence or the deterioration of diabetic retinopathy. There were no significant differences between patients who were treated with perindopril/indapamide and the control group. Possible explanations could be based on the high proportions of unblinded medication with perindopril, even in the placebo group (55%), and the intensive insulin and statin therapy. Detailed analyses are expected from the sub-study Advance Retinopathy Measurements (AdRem) (e26).
In the DIRECT study (15) , the angiotensin receptor blocker candesartan was used at a dosage of up to 32 mg, to guarantee maximal blockade of the retinal RAS ( Figure 5 ). In the DIRECT-Prevent 1 trial (18), the incidence of diabetic retinopathy in type 1 diabetes was examined (blood pressure at the start of the study: 116/72 mm Hg). Two or more steps progression (ET-DRS scale) was used and a trend (-18%; p = 0.0508) was shown. With three or more steps, the incidence was significantly reduced by 35% (p = 0.003).
However, in the DIRECT-Protect 1 trial (18), the progression in type 1 diabetes was examined (49% of the patients had only micro-aneurysms). Only nominal changes were found for the progression and regression of three or more steps on the ETDRS scale. In DIRECTProtect 2 (19) , the progression of retinopathy in type 2 diabetes was examined. At the beginning, 29% of the patients had only micro-aneurysms in the worse eye, 54% mild non-proliferative diabetic retinopathy and 17% moderate NPDR. After a median follow-up of 4.7 years, retinopathy had improved to a greater extent in patients receiving 32 mg candesartan than in those receiving placebo (p = 0.003). However, the progression (three or more steps on the ETDRS scale) was decreased by 13% (p = not significant). In contrast, regression (three or more steps on the ETDRS scale) was relatively increased by 34% (p = 0.009).
In exploratory analyses, the results of the DIRECT study were adjusted for various factors, including blood pressure (about 2 to 3 mm Hg in favor of candesartan). In all cases, the effects on diabetic retinopathy were robust, i.e., the effect sizes and p-values after adjustment only changed quantitatively but not qualitatively.
Macrovascular prognosis with microalbuminuria and retinopathy
The detection of microalbuminuria and retinopathy does not only indicate an increased risk in patients for the development of proliferative diabetic retinopathy and nephropathy. The association of these risk factors with cardiovascular events has also been described in studies.
Microalbuminuria
There is a positive clinical correlation between the extent of albumin excretion and cardiovascular events. The adjusted relative risk of macrovascular events in the MICRO-HOPE study was clearly increased when microalbuminuria was present (relative risk [RR]: 1.83), as well as the total mortality (RR: 2.09) and admissions to hospital because of heart failure (RR: 3.23) (e27). The one-year mortality was increased by the factor of 3.4 to 5.0 after cardiac infarction and the presence of microalbuminuria, at a threshold of 50 mg albumin/g creatinine on the first day after the event (e28) .
In an analysis of the LIFE study (e29), the patients were classified into four groups by the rate of albumin excretion at the start of the therapy and after one year of observation. Additionally, the incidence of the combined endpoint of cardiovascular death, nonfatal stroke, and myocardial infarction was evaluated. Patients under treatment with AT 1 blockers exhibited a disproportionate reduction in albuminuria and had clearly fewer cardiovascular events (1.8% or 3.4%) than patients with smaller changes in albuminuria (2.7% or 6.1%; p<0.001).
FIGURE 4
Options for blocking the renin-angiotensin system (RAS) through angiotensin receptor blockers (AT 1 blockers), ACE inhibitors, and renin inhibitors. The figure illustrates that metabolism of angiotensin I is complex and that there are different ways of circumventing single blockers of the RAS. For example, ACE inhibitors interfere in the metabolism of angiotensin I, angiotensin (1) (2) (3) (4) (5) (6) (7) (8) (9) , angiotensin (1) (2) (3) (4) (5) (6) (7) , and bradykinin. ACE, angiotensin converting enzyme, ACE-2, ACE-related carboxypeptidase, NEP, neutral endopeptidase, PEP, prolyl endopeptidase, CBP, carboxypeptidase (modified according to: Schindler C, Bramlage P, Kirch W, Ferrario CM: Role of the vasodilator peptide angiotensin [1] [2] [3] [4] [5] [6] [7] e30) . With a hazard ratio (HR) of 1.61 for NPDR and 3.75 for PDR, the risk for men was also increased after multiple adjustment for classical risk factors (women: HR = 1.67 for NPDR and HR = 3.81 for PDR). When the risk factors were adjusted for the presence of hypertension and advanced nephropathy, the increase in risk for NPDR lost its significance. In a cohort of 11 612 persons, Wong et al. examined whether diabetic retinopathy is a pathogenic factor for the development of heart failure (e31). The incidence in patients with retinopathy was 15.1% after 7 years and 4.8% in the control group (p<0.001). Even after adjusting for the known risk factors, the relative risk was still 1.96.
Comorbidity of microalbuminuria and retinopathy
The diagnosis of diabetic nephropathy is supported by simultaneous diagnosis of retinopathy (20, 21) . With young type 1 diabetics, there is no initial connection between the appearance of microalbuminuria or retinopathy and changes in coronary perfusion (e32) . However, over a period of 12 years, microalbuminuria and retinopathy were linked with the development of cardiac disease (e33) .
In a group of 4416 type 2 diabetics, Tong et al. examined how the diagnosis of retinopathy, as well as of micro-or macroalbuminuria, affects vascular events (22) . If retinopathy was present, the risk was only slightly increased-with a hazard ratio (HR) of 1.61-but increased more when accompanied by microalbuminuria (HR: 2.59) or macroalbuminuria (HR: 6.83). HR for microalbuminuria alone was 1.93 and for macroalbuminuria 4.34. Ioannidis et al. pursued the question as to whether an examination of the eyes and the excretion of albumin in urine could be a simple screening measure to increase the accuracy of cardiac SPECT examination. The answer is yes. Patients with microalbuminuria and retinopathy had a positive scan in 94% of cases (n = 15 of 16) and 83% of all patients (n = 30 of 36) with a negative scan showed neither microalbuminuria nor retinopathy (23) .
Odds ratio for progression of retinopathy. Overview of the results of the studies of Larsen et al., Chase et al., Ravid et al. , and the EUCLID-, ADVANCE-and DIRECT studies. ETDRS, Early Treatment of Diabetic Retinopathy Study Scale (15-19, e23-e26) b Blood sugar, lipids, and blood pressure must be adjusted to within a near normal range, preferably with ACE inhibitors or AT 1 blockers.
b Adjusting these risk factors to a near normal range decreases additional microvascular complications and in the long-term reduces cardiovascular morbidity and mortality.
b Interdisciplinary collaboration between diabetologists, nephrologists, cardiologists and ophthalmologists, as well as general practitioners and internists seems to be necessary for these diseases.
